Maxitrol, (1 mg + 3500 IU + 6000 IU)/ml, Eye Drops, Suspension
Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate
Infection.Eye Inflammation can be Caused by Infection or Other Factors
Penetrating the Eye or Eye Injuries.
Corticosteroids (in this Case, Dexamethasone) are Used to Prevent and Reduce
Eye Inflammation. The Antibacterial Medications in the Drops (in this Case, Neomycin
Sulfate and Polymyxin B Sulfate) are Active Against Most Pathogenic Bacteria Causing
Eye Infections.
For Ophthalmic Use Only.
Additionally, Local Use of Neomycin May Lead to Redness, Irritation, and Discomfort of the Skin.
If the Patient Experiences Blurred Vision or Other Vision Disturbances, They Should Consult Their Doctor.
If the Patient Has Glaucoma, the Treatment Duration Should be Limited to Two Weeks, Unless the Doctor Recommends Otherwise.
The Medication Should be Used for as Long as the Doctor Recommends.If the Symptoms Worsen or Do Not Improve, the Patient Should Consult Their Doctor.
The Safety and Efficacy of Maxitrol in Children Have Not Been Documented, Therefore, its Use is Not Recommended in this Age Group.
The Patient Should Inform Their Doctor or Pharmacist About All Medications They are Currently Taking or Have Recently Taken, as Well as Any Medications They Plan to Take, Including Those Available Without a Prescription.
Particularly, the Patient Should Inform Their Doctor if They are Taking:
If the Patient is Using Other Eye Drops or Ointments, They Should Wait at Least 5 Minutes Between Administrations of Different Medications. Eye Ointments Should be Used Last.
If the Patient is Pregnant or Breastfeeding, Thinks They May be Pregnant, or Plans to Have a Child, They Should Consult Their Doctor or Pharmacist Before Using this Medication.
This Medication is Not Recommended During Pregnancy or Breastfeeding.
Maxitrol Has No or Negligible Influence on the Ability to Drive and Use Machines.
For a While After Administering Maxitrol, Vision May be Blurred. The Patient Should Not Drive or Use Machines Until this Symptom Resolves.
The Medication Contains 0.04 mg of Benzalkonium Chloride per Milliliter (0.04 mg/ml).
Benzalkonium Chloride May be Absorbed by Soft Contact Lenses and Change Their Color. The Patient Should Remove Their Contact Lenses Before Administering the Drops and Wait at Least 15 Minutes Before Reinserting Them.
Benzalkonium Chloride May Also Cause Eye Irritation, Especially in Patients with Dry Eye Syndrome or Corneal Disorders (the Transparent Layer on the Front of the Eye). If the Patient Experiences Any Abnormal Sensations in the Eye, Stinging, or Eye Pain After Using the Medication, They Should Consult Their Doctor.
Maxitrol Should Always be Used as Directed by the Doctor. If the Patient Has Any Doubts, They Should Consult Their Doctor or Pharmacist.
Maxitrol is Intended Exclusivelyfor Ophthalmic Use; One Package of the Medication Should be Used by OnlyOne Patient.
If the Protective Cap is Loose After Removing the Seal, it Should be Removed Before Using the Medication.
The Patient Should Close Their Eyelid and Gently Press the Nasolacrimal Duct (Tear Duct) with Their Finger. This Helps Reduce the Absorption of the Medication into the Bloodstream After Ophthalmic Administration.
In Mild Cases, One to Two Drops are Administered into the Conjunctival Sac (Sacs) Four to Six Times a Day.
In Severe Cases, One to Two Drops are Administered Every Hour. The Medication is Gradually Administered in Decreasing Doses, and its Use is Discontinued After the Inflammatory Symptoms Resolve.
The Doctor Will Determine the Duration of Treatment. The Patient Should Not Discontinue Treatment Prematurely.
Failing to Follow this Instruction May Cause Infection of the Drops.
If the Drop Does Not Enter the Eye,You Should Repeat the Attempt to Administer the Drop Correctly.
In Case of Local Overdose of Maxitrol, the Eye (Eyes) Should be Rinsed with Lukewarm Water.
The Medication Should Not be Used Until the Next Scheduled Dose.
If a Dose is Missed, the Next Scheduled Dose Should be Taken. However, if There is Not Much Time Left Before the Next Dose, the Missed Dose Should be Omitted and the Normal Administration Schedule Resumed. Do NotTake a Double Dose to Make Up for the Missed Dose.
If You Have Any Further Questions About Using this Medication, Consult Your Doctor or Pharmacist.
Like All Medications, Maxitrol Can Cause Side Effects, Although Not Everybody Gets Them.
If the Patient Experiences Allergic Reactions, Including Rash, Face, Lip, Tongue, and (or)
Throat Swelling, Which May Cause Difficulty Breathing or Swallowing, or Other Severe
Side Effects, They Should Discontinue Using Maxitrol and Immediately Consult Their Doctor or the Emergency Department of the Nearest Hospital.
During Treatment with Maxitrol, the Following Side Effects Have Been Observed:
Uncommon(May Occur in Less Than 1 in 1000 Patients): Keratitis, Increased Intraocular Pressure, Eye Itching, Eye Discomfort, Eye Irritation.
Frequency Not Known(Frequency Cannot be Estimated from the Available Data):
Hypersensitivity, Headache, Corneal Ulceration, Blurred Vision, Light Sensitivity, Pupil Dilation, Ptosis, Eye Pain, Eye Swelling, Foreign Body Sensation in the Eye, Eye Redness, Increased Lacrimation, Severe Skin Reactions (Stevens-Johnson Syndrome), Blurred Vision, Excessive Hair Growth on the Body (Especially in Women), Muscle Weakness, and Muscle Mass Loss, Purple Streaks on the Skin, Increased Blood Pressure, Irregular Menstruation or Amenorrhea, Changes in Protein and Calcium Levels in the Body, Growth Inhibition in Children and Adolescents, and Edema and Weight Gain, Especially on the Trunk and Face (Cushing's Syndrome) (See Section 2 "Warnings and Precautions").
If the Patient Experiences Any Side Effects, Including Any Side Effects Not Listed in the Leaflet, They Should Inform Their Doctor, Pharmacist, or Nurse. Side Effects Can be Reported Directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, Website: https://smz.ezdrowie.gov.pl.
Reporting Side Effects Helps Collect More Information on the Safety of the Medication.
If Any of the Symptoms Worsen or if Other Symptoms Not Listed in this Leaflet Occur, the Patient Should Inform Their Doctor.
To Avoid Infection of the Drops, the Bottle Should be Discarded 4 Weeks After First Opening. The Date of First Opening Should be Written in the Space Provided Below.
Date of First Opening: ...............
The Medication Should be Stored Out of Sight and Reach of Children.
Do Not Store Above 25°C.
Do Not Store in the Refrigerator.
Store the Bottle Upright.
Store the Package Tightly Closed.
Do Not Use the Medication After the Expiration Date Stated on the Package. The Expiration Date Refers to the Last Day of the Specified Month.
Medications Should Not be Disposed of in Wastewater or Household Waste. The Patient Should Ask Their Pharmacist How to Dispose of Unused Medications. This Will Help Protect the Environment.
The Active Substances of the Medication are:
Dexamethasone 1 mg/ml
Neomycin Sulfate 3500 IU/ml
Polymyxin B Sulfate 6000 IU/ml
The Excipients are: Sodium Chloride, Polysorbate 20, Benzalkonium Chloride, Hypromellose, Purified Water.
The Medication May Contain Minimal Amounts of Hydrochloric Acid and (or) Sodium Hydroxide to Adjust the pH.
Maxitrol Eye Drops are a Non-Clear Suspension with a Color Ranging from White to Light Yellow.
It is Available in a 5 ml Low-Density Polyethylene (LDPE) Bottle with a Dropper, in a Cardboard Box.
For More Detailed Information, the Patient Should Consult the Marketing Authorization Holder or the Parallel Importer.
Novartis s.r.o., Na Pankráci 1724/129, 140 00 Prague 4, Czech Republic
Novartis Pharma GmbH, Roonstrasse 25 und Obere Turnstrasse 8-10, 90429 Nuremberg, Germany
Siegfried El Masnou, S.A., Camil Fabra, 58, 08320 El Masnou, Barcelona, Spain
Novartis Farmacéutica, S.A., Gran Via de les Corts Catalanes 764, 08013 Barcelona, Spain
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing Authorization Number in the Czech Republic, the Country of Export:64/631/70-C
[Information About the Trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.